Characterization of Clostridium difficile isolates collected during a phase 2b clinical study with SYN-004 (ribaxamase) for the prevention of C. difficile infection

Anaerobe. 2018 Oct:53:30-33. doi: 10.1016/j.anaerobe.2018.07.002. Epub 2018 Jul 5.

Abstract

During a Phase 2b study with SYN-004 (ribaxamase) for prevention of Clostridium difficile infection (CDI) conducted in North America and Eastern Europe, 45 C. difficile isolates from subjects with laboratory-confirmed CDI and or colonized with C. difficile were collected and characterized. Several C. difficile PCR ribotypes, including 027 and 198, were identified.

Keywords: Clinical isolates; Clostridium difficile infection; PCR ribotyping.

Publication types

  • Review

MeSH terms

  • Clinical Trials, Phase II as Topic
  • Clostridioides difficile / classification*
  • Clostridioides difficile / genetics
  • Clostridioides difficile / isolation & purification*
  • Clostridium Infections / microbiology*
  • Clostridium Infections / prevention & control
  • Europe, Eastern
  • Humans
  • North America
  • Recombinant Proteins / administration & dosage
  • Ribotyping*
  • beta-Lactamases / administration & dosage

Substances

  • Recombinant Proteins
  • SYN-004
  • beta-Lactamases